Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)

Mapping Intimacies ◽

10.1158/1538-7445.sabcs15-s2-04 ◽

2016 ◽

Cited By ~ 25

Author(s):

G von Minckwitz ◽

S Loibl ◽

A Schneeweiss ◽

CT Salat ◽

M Rezai ◽

...

Keyword(s):

Breast Cancer ◽

Survival Analysis ◽

Neoadjuvant Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Trial ◽

Her2 Positive ◽

Randomized Phase Ii ◽

Early Survival

Download Full-text

Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto)

Annals of Oncology ◽

10.1093/annonc/mdx362.014 ◽

2017 ◽

Vol 28 ◽

pp. v49 ◽

Cited By ~ 4

Author(s):

M. Untch ◽

A. Schneeweiss ◽

C. Salat ◽

M. Rezai ◽

D-M. Zahm ◽

...

Keyword(s):

Breast Cancer ◽

Survival Analysis ◽

Neoadjuvant Therapy ◽

Early Breast Cancer ◽

Triple Negative ◽

Phase Ii Trial ◽

Her2 Positive ◽

Term Survival ◽

Randomized Phase Ii

Download Full-text

Neoadjuvant Therapy with Weekly Nanoparticle Albumin‐Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011‐02), a Multicenter, Non‐Randomized, Phase II Trial, with a Companion Biomarker Analysis

The Oncologist ◽

10.1634/theoncologist.2017-0052 ◽

2017 ◽

Vol 22 (11) ◽

pp. 1301-1308 ◽

Cited By ~ 6

Author(s):

Miguel Martín ◽

José I. Chacón ◽

Antonio Antón ◽

Arrate Plazaola ◽

Elena García‐Martínez ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Therapy ◽

Cancer Patients ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Breast Cancer Patients ◽

Randomized Phase Ii ◽

Biomarker Analysis

Download Full-text

LAPATAX: A randomized phase II trial of FEC-docetaxel combined with lapatinib and/or trastuzumab as neoadjuvant therapy of HER2-positive breast cancer—EORTC 10054 trial.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.tps116 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. TPS116-TPS116 ◽

Cited By ~ 2

Author(s):

D. A. Cameron ◽

S. Marreaud ◽

K. Zaman ◽

A. Bodmer ◽

J. Pierga ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Therapy ◽

Phase Ii ◽

Phase Ii Trial ◽

Her2 Positive ◽

Her2 Positive Breast Cancer ◽

Randomized Phase Ii ◽

Positive Breast Cancer

Download Full-text

Faculty Opinions recommendation of Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734565867.793581155 ◽

2020 ◽

Author(s):

David Potter

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Neoadjuvant Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Randomized Phase Ii ◽

Estrogen Receptor Positive

Download Full-text

Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial

Annals of Oncology ◽

10.1093/annonc/mdy211 ◽

2018 ◽

Vol 29 (8) ◽

pp. 1777-1783 ◽

Cited By ~ 26

Author(s):

M. Ignatiadis ◽

S. Litière ◽

F. Rothe ◽

S. Riethdorf ◽

C. Proudhon ◽

...

Keyword(s):

Breast Cancer ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Early Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii

Download Full-text

Abstract OT3-3-08: Eribulin/Cyclophosphamide versus Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer: A Randomized Phase II Trial of the Sarah Cannon Research Institute

10.1158/0008-5472.sabcs12-ot3-3-08 ◽

2012 ◽

Author(s):

DA Yardley ◽

JD Hainsworth ◽

M Shastry ◽

L Finney ◽

HA Burris

Keyword(s):

Breast Cancer ◽

Neoadjuvant Therapy ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Randomized Phase Ii ◽

Research Institute

Download Full-text

Abstract S6-07: Comparison of 12 weeks neoadjuvant Nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple- negative breast cancer: WSG-ADAPT TN randomized phase II trial

10.1158/1538-7445.sabcs15-s6-07 ◽

2016 ◽

Cited By ~ 6

Author(s):

O Gluz ◽

U Nitz ◽

C Liedtke ◽

M Christgen ◽

K Sotlar ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Trial ◽

Randomized Phase Ii

Download Full-text

Abstract P1-09-05: The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)

10.1158/1538-7445.sabcs16-p1-09-05 ◽

2017 ◽

Cited By ~ 1

Author(s):

N Harbeck ◽

UA Nitz ◽

C Matthias ◽

R Kates ◽

M Braun ◽

...

Keyword(s):

Breast Cancer ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Phase Ii ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Her2 Positive ◽

Hormone Receptor Positive ◽

Apoptosis Markers

Download Full-text

Abstract PD3-08: A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab

10.1158/1538-7445.sabcs17-pd3-08 ◽

2018 ◽

Cited By ~ 4

Author(s):

B Xu ◽

F Ma ◽

Q Ouyang ◽

W Li ◽

Z Jiang ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Her2 Positive ◽

Randomized Phase Ii ◽

Previously Treated

Download Full-text

Abstract P2-08-19: Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC)

10.1158/1538-7445.sabcs18-p2-08-19 ◽

2019 ◽

Author(s):

MJ Wongchenko ◽

M Oliveira ◽

C Saura ◽

P Nuciforo ◽

I Calvo ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Phase Ii

Download Full-text